investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…
biosimilar Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To begin, would you please introduce yourself and Elea to our readers? I joined Elea four years ago as general manager,…
similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the way to consolidating its different business lines and becoming a pure pharmaceutical company. 2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…
Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
Biosimilars Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future and how a relationship with China would be mutually beneficial for both countries. Since Taiwan Food & Drug Administration’s founding…
Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…
APAC Region PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a company you founded in 1999. Today, does Taiwan continue to make sense as PAREXEL’s APAC headquarters? We believe that it…
Austroplant Arzneimittel Can you give our readers a snapshot of Austroplant’s scope of activities and its structure in Austria and the central European market? Austroplant/Dr Peithner belongs to the Schwabe Group, the worldwide leader in herbal medicine products. It was sold to the Schwabe Group as a family business in 2009. Dr.…
Litha Healthcare Group Limited Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main milestones in the company’s development since then? In 2005 and 2006, we were in essence a vaccines company called Litha…
Novo Nordisk India Private Limited Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this relatively early entry? Traditionally, Novo Nordisk’s strategy has been to be in the market very early. We aspire to create…
See our Cookie Privacy Policy Here
